Schizophrenia: Reversal of atypical antipsychotic drug-induced obesity and its related metabolic disorders [ 2012 - 2016 ]

Research Grant

Researchers: Prof Xu-Feng Huang (Principal investigator) ,  Dr Francesca Fernandez-Enright ,  Prof Chao Deng

Brief description Atypical antipsychotic drugs such as olanzapine are commonly used to treat mental illnesses such as schizophrenia. While these drugs are effective, their side effects of obesity and metabolic disorders are a major hurdle leading to a serious lack of compliance in taking medication. This project aims to develop better antipsychotic treatment with reduced side-effects including obesity and metabolic disorders for mental illness patients.

Funding Amount $AUD 619,854.25

Funding Scheme Project Grants

Notes Standard Project Grant